The Indian Practitioner

Open Access Open Access  Restricted Access Subscription Access
Open Access Open Access Open Access  Restricted Access Restricted Access Subscription Access

Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence


Affiliations
1 Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, India
2 Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India
3 Department of ENT, Trustwell Hospitals, Bangalore, India
4 Department of ENT, Jagtap Hospital, Dhule, India
5 Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, India
6 Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
     

   Subscribe/Renew Journal


Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.

Keywords

Recurrent Aphthous Stomatitis, Rebamipide.
Subscription Login to verify subscription
User
Notifications
Font Size



  • Rebamipide in Recurrent Aphthous Stomatitis: Review of Indian Evidence

Abstract Views: 381  |  PDF Views: 0

Authors

K. R. Meghanadh
Department Otorhinolaryngology and Head and Neck Surgery, MAA ENT Hospital, Hyderabad, India
Mandeep Kaur
Department of Oral Medicine and Radiology, Faculty of Dentistry, Jamia Millia Islamia, New Delhi, India
Deepak Haldipur
Department of ENT, Trustwell Hospitals, Bangalore, India
Charuhas Jagtap
Department of ENT, Jagtap Hospital, Dhule, India
N. K. Soni
Department of Internal Medicine & Diabetology, Yatharth Super Speciality Hospital, Greater Noida, India
Ashwin Kotamkar
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Aaditi Phadke
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Parthasarathy Muralidharan
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India
Amit Qamra
Department of Medical Affairs, Macleods Pharmaceuticals Ltd., Mumbai, India

Abstract


Recurrent aphthous stomatitis (RAS) is one of the commonly observed disease of the oral cavity and the prevalence ranges from 5 to 60%. Despite its high prevalence, the exact pathophysiology of the disease remains unknown. Multiple etiologic factors, followed by three stages of the disease, and types based on severity, with addition of pain and inflammation makes the management challenging for the clinician. A number of drugs are available for the treatment having their own advantages and limitations. In this narrative review, we review the available Indian evidence with Rebamipide in RAS. Indian clinical evidence clearly establishes the safety and efficacy of rebamipide in the management of RAS. Thus, considering the benefits of reduced duration of pain, accelerated healing and decreased recurrence, we conclude that the current Indian evidence supported by our clinical experience establishes the role of Rebamipide in RAS. Hence, we recommend Rebamipide may be considered as a first line treatment option in RAS.

Keywords


Recurrent Aphthous Stomatitis, Rebamipide.

References